Progress your immunotherapy drug discovery by using organoids, the most clinically-relevant in vitro platform now available for immuno-oncology applications. Use our unique organoid and non-autologous immune cell co-culture platform to benefit from:
Our organoid and immune cell co-culture platform is available to:
Organoids can be engineered to express your desired immunotherapy target or to detect tumor organoid killing by luciferase or fluorescence.
Tumor organoids are developed directly from patient tumors and matched healthy tissue using patented and exclusive HUB technology. Our well-characterized and ample patient-derived xenograft (PDX) collection is also available as an alternative source of human tumor tissue. PDX models allow additional tumor organoid development across more indications and to truly represent patient population diversity for biomarker identification and hypothesis generation.